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1. 1 Souhrn 
 
Název práce   
Klinické použití neopterinu, laboratorního biomarkeru imunitní aktivace, v určení 
prognózy, monitorování odpovědi na léčbu a komplikací u pacientů s nádorovým 
onemocněním  
Uvod  
Neopterin je biomarker imunitní aktivace, syntetizovaný z GTP v reakci katalyzované 
enzymem GCH-1. Hladiny neopterinu odrážejí reakci organismu na zánětlivé stavy, 
jako jsou infekce, poranění, chronických onemocnění a rakovina. Hladina kolísá i v 
průběhu všech modalit protinádorové terapie, která ovlivňuje činnost imunitního 
systému. Vysoká hladina neopterinu je spojena se špatnou prognózou u nádorových 
onemocnění.  
Cíl  
Ověření klinického použití neopterinu, ve stanovení prognózy, monitorování 
odpovědi na léčbu a komplikací u pacientů s rakovinou.  
Metodologie  
Ve dvou částech studie, sériové neopterinu v moči byly měřeny ve dvou různých 
kohortách pacientů, kteří podstoupili protinádorovou terapii. V první části, byly 
analyzovány vzorky od 45 pacientů s diagnózou metastazujícího kolorektálního 
karcinomu, kteří byli léčeni chemoterapií v kombinaci s cetuximabem. Ve druhé části 
byly analyzovány vzorky 10 pacientek B s diagnózou gynekologické malignity, 
většinou karcinomu děložního hrdla, podstupujích chemoradioterapii.  
 
Výsledky  
U nemocných s metastatickým kolorektálním karcinomem byly vyšší hladiny 
neopterinu spojeny se špatnou prognózou. Hladina neopterinu korelovala s 
koncentrací  hemoglobinu, počtem bílých krvinek a koncentrací CEA. U nemocných s 
gynekologickými malignitami byly výchozí hladiny neopterinu vyšší. Byl pozorován 










Tato data prokazují potenciální klinické využití neopterinu, v prognóze, monitorování 
odpovědi na léčbu a komplikací u pacientů s rakovinou. Další studie na větších 






























1. 2 Summary  
 
Title  
Clinical use of neopterin, a laboratory biomarker of immune activation, in prognosis,  
monitoring response to therapy and complications in cancer patients 
Introduction 
Neopterin is a biomarker of immune activation and is synthesized from GTP 
in a reaction catalyzed by enzyme GCH-1.  Neopterin levels reflect the body’s 
response to inflammatory conditions such as infections, injuries, chronic diseases, and 
cancer.  Its levels also fluctuate with anticancer therapies that demonstrate immune 
activity. Remarkably neopterin has also been found to be a marker of poor prognosis 
in cancer.  
Aim  
To investigate clinical use of neopterin, a biomarker of immune response, in 
the assessment of prognosis, monitoring response to therapy, and complications in 
cancer patients. 
Methodology  
In a two-part study, serial urinary neopterin were measured in two different 
cohorts of patients who underwent anticancer therapy. In part one, samples from 45 
patients with diagnosis of metastatic colorectal cancer who were being treated with 
chemotherapy + cetuximab were analyzed.  In part two, samples from 10 patients with 
diagnosis of gynecological malignancy, mostly cervical cancer, and undergoing 
chemoradiotherapy were analyzed.   
Results 
In patients with metastatic colorectal carcinoma, higher neopterin levels were 
associated with poor prognosis. In this cohort, neopterin levels showed correlation to 
hemoglobin levels, white cell count and CEA.  In patients with gynecological cancer, 
pretreatment neopterin levels were generally higher.  No association of therapy-
associated changes in neopterin levels were observed, however, we were able to 









With our data we have been able to demonstrate the potential clinical uses of 
neopterin in prognosis, monitoring response to therapy and complications in cancer 
patients. However, much larger studies with different tumor types could be performed 










































5-FU – 5 Fluorouracil 
(ADCC)- Antibody dependent cell-mediated cytotoxicity      
AIDS- acquired immunodeficiency syndrome 
BMIS!Body!Mass!Index!
BH4- Tetrahydrobiopterin  
Ca++- Calcium Ion  
CD- Cluster of differentiation  
CDC complements dependent cytotoxicity 
DC dendritic cells (DCs)  
EGFR- Epidermal Growth Factor Receptor  
GTP – Guanosine triphosphate  
GCH 1 - GTP-cyclohydrolase I 
G-CSF – Granulocyte colony stimulating factor 
GM-CSF – Granulocyte monocyte colony stimulating factor 
HIV – Human immunodeficiency Virus 
HOCL- Hypochlorus acid  
HSP – Heat shock Protein  
iNOS - inducible nitric oxide synthase 
IDO - indoleamine (2,3)-dioxygenase 
IFN- alpha – Interferon Alpha 
IFN-gamma – Interferon Gamma 
IL-2 – Interleukin 2 
IL- 6  - Interleukin 6 
IL-10 – Interleukin 10 
IL-12 - Interleukin 12, 
Kyn/tryp - kynurenine to tryptophan ratio 
KRAS - Kirsten rat sarcoma viral oncogene homolog  
LPS - lipopolysaccharide 
mAb- monoclonal antibody 
NK - natural killer 
NF-κB - nuclear factor-κB 
OSA – Obstructive sleep apnea  
PTPS 6 - Pyruvoyltetrahydropterin synthase 
rIFN- gamma   recombinant IFN-gamma 
RT- Radiotherapy  
TNF-alpha   Tumour necrosis factor Alpha  
Tryp - Tryptophan 
TAM - Tumour-associated macrophages 








Malignant tumors  elicit host response that involves both the adaptive and 
innate immune systems [Melichar et al 2006a].   Body’s defense mechanism is 
designed to eliminate aberrant cells.  However, the development of cancers 
demonstrates that these responses are not always sufficient to preclude malignancy. It 
is now evident that cancerous cells manage to escape immune recognition and 
elimination [Dranoff 2004] by evolving certain strategies to escape from immune 
surveillance. This quality of cancerous cell is known to be an important aspect in 
early pathogenesis of malignant disease [Boon and Der Bruggen 1996].  In addition, 
the crosstalk between normal and neoplastic cells is a factor that influences various 
stages of carcinogenesis [Hanahan & Weinberg 2000].  An important variable that 
might prove decisive in molding the host reaction is the mixture of cytokines that is 
produced in the tumor microenvironment [Dranoff & Mulligan 1995].  Thus the 
immune response to cancer cells and the escape mechanism of latter could be studied 
by studying the cytokines, the cellular components and the products of host response 
in tumor microenvironment and also in various visceral fluids [Melichar et al 1998].   
 IFN-gamma is one such cytokine produced by the T-lymphocytes and natural 
killer cells.  Interestingly, IFN-gamma has been found to play an important role in 
regulating tumor growth [Ikeda et al 2002] in different ways. For example IFN-y may 
play two distinct roles in expressing the antitumor efficacy of IL-12: one to support 
the T-cell acceptability of tumor masses, and the other to mediate the antitumor 
effects of migrated T cells [Ogawa et al 1998].     
Upon stimulation by IFN-gamma the monocyte/macrophage and dendritic 
cells show enhanced production of pteridines such as neopterin [Murr et al 2002, 
Weirleitner et al 2002].  Other cell types like, endothelial cells [Andert et al 1992], B-
lymphocytes [Hoffmann et al 1992], and kidney cells [Mountabarrik et al 1994] also 
produce neopterin.  However, neopterin output from monocyte/macrophages has been 
found to be higher several folds to several orders of magnitude [Melichar et al 2006a]. 
In addition to the activation of immune system high neopterin production is also 
associated with increased production of reactive oxygen species and with low serum 
concentrations of antioxidants like α-tocopherol.  Hence, it can also be regarded as a 





[Murr et al 2002]. Therefore, by measuring neopterin not only the extent of cellular 
immune activation, but also the extent of oxidative stress can be estimated [Murr et al 
2002, Hoffmann et al 2003]. 
Neopterin was first isolated from human urine by Sakurai and Goto in 1960’s 
[Sakurai and Goto 1967]. It was found to be one of the molecules responsible for the 
fluorescence of urine in cancer patients [Wachter et al 1989]. Fuchs et al. highlighted 
neopterin’s association to immune system in in the early 1980s when they proposed 
neopterin to be a marker of immune activation [Fuchs et al 1984]. 
Chemistry and synthesis  
 
 
FIGURE 1.  Neopterin:  2-amino -4-oxo-6 –(derythro-1', 2', 3'-trihydroxypropyl)-pteridine  
[1] 
 
Chemically, neopterin is 2-amino -4-oxo-6 –(derythro-1', 2', 3'-trihydroxypropyl)-
pteridine, which is an unconjugated pteridine.  It is synthesized from Guanosine 
Triphosphate (GTP) by the action of GTP cyclohydrolase 1 (GCH-1) [Melichar et al 
2006a]. 
In a reaction catalyzed by GCH-1, GTP is converted to 7, 8- 
dihydroneopterintriphosphate, which is the first step towards formation of neopterin 
[Becker et al 2013].      
Next, 7, 8- dihydroneopterintriphosphate, is metabolized in two different ways 
depending on the location.  Pyruvoyltetrahydropterin synthase (PTPS) is the enzyme 
responsible for conversion of 7, 8- dihydroneopterintriphosphate to 5,6,7,8 – 
Tetrahydrobiopterin (BH4). Most of the somatic cells produce BH4 by this route; 





IFN gamma can stimulate the production of GCH-1 in various cell types. 
However, in macrophages the degree of induction of GCH-1 activity is significantly 
higher than the constitutively present 6-pyruvoyl tetrahydropterin synthase (PTPS) 
activity. [Murr et al 2002]  
Thus in macrophages and dendritic cells the IFN gamma induced GCH-1 
production leads to increased accumulation of 7, 8- dihydroneopterintriphosphate 
which acts as the substrate of neopterin production.  In contrast, in other cells GCH-1 
activity always remains lower than the PTPS synthase activity leading to BH4 
synthesis without the accumulation of large amounts of neopterin derivatives [Werner 
et al 1990].  
Though no clear reason for the low expression PTPS synthase in human 
macrophages has been identified, exon skipping has been demonstrated to be a 
mechanism responsible [Leitner et al 2003]. Leitner et al demonstrated that PTPS 
transcripts in macrophages lack exon 3 resulting in premature stop codon.  PTPS 
transcripts lacking exon 3 are also characteristic of dendritic cells, myeloid cell lines, 
B-lymphocytes, and T-lymphocytes, but monocytes/macrophages remain the most 





FIGURE 2. In various cells the Th1-type cytokine IFN-gamma (IFN-γ) induces the GTP-
cyclohydrolase I (GCH I) to produce 7, 8-dihydroneopterintriphosphate. Due to a deficiency 
in 6 -pyruvoyltetrahydropterin synthase (PTPS) in human monocyte-derived macrophages 
and dendritic cells, the production of 5, 6, 7, 8-tetrahydrobiopterin is almost zero and 






The next step toward the production of neopterin involves conversion of 7, 8- 
dihydroneopterintriphosphate to neopterin.  This is carried out by the 
dephosphorylation of 7, 8- dihydroneopterintriphophate and further oxidation. HOCL 
is a cytocidal compound that has been recognized as the agent that can oxidize 7, 8- 
dihydroneopterintriphophate to form neopterin [Widner et al 2000, Gieseg et al 2001]. 
7, 8-dihyrdoneopterin is the intermediate in the process of formation of 
neopterin. It has been found that the ratio of 7, 8-dihydroneopterin to neopterin is 
constant [Fuchs et al 1989], and therefore neopterin concentrations can be used to 
assess in vivo GTP cyclohydrolase I activity and consequently, activation of the 
macrophages [Melichar et al 2006a].   
 The macrophages produce neopterin out of the 7, 8-
dihydroneopterintriphosphate intermediate at the expense of 5, 6, 7, 8-
tetrahydrobiopterin (BH4). As a result the levels of this cofactor required for synthesis 
of several aromatic amino acid hydroxylases and nitric oxide synthases runs low in 
macrophages. Fuchs et al. have proposed this biochemical peculiarity of pteridines’ 
biochemistry as a reason for hampered nitric oxide production in human monocyte-

























FIGURE 4: Induction of neopterin formation in brain cells. Proinflammatory cytokines like 
interferon-γ (IFN-γ) induce expression of GTP-cyclohydrolase I in various brain cells. As an 
intermediate product 7, 8-dihydroneopterin-triphosphate is produced which is further 
converted by pyruvoyl-tetrahydropterin synthase (PTPS) to form 5, 6, 7, 8-
tetrahydrobiopterin (BH4), the cofactor of several aromatic amino acid monooxygenases that 
are involved in the production of tyrosine, L-DOPA, serotonin and nitric oxide. Different 
from neurons, monocytic cells possess only low constitutive activity of PTPS. Thus, 7, 8-
dihydroneopterin-triphosphate does not undergo conversion to BH4, rather it is 
dephosphorylated and oxidized to neopterin in non-enzymatic reactions. [Hagberg 2010]  
 
The above illustration shows the difference between pteridine metabolism by 










Neopterin is eliminated by the kidneys and changes in the neopterin 
concentrations in serum are reflected by corresponding alterations of urine levels as 
long as renal function is normal [Fuchs et al 1994b].  A strong correlation between 
urinary and serum neopterin levels has been established [Fuchs et al 1988a] and in the 
absence of renal insufficiency both serum (or plasma) and urine may be used for the 
measurement of neopterin [Melichar et al 2006a]. 
 Renal clearance of neopterin is similar to that of creatinine. Therefore, neopterin 
per creatinine ratios in urine are not influenced by renal impairment [Fuchs et al 
1994b]. Unlike that, blood neopterin concentrations depend on renal function; 
reduced renal excretion causes accumulation of neopterin in blood and one may find 
extremely high values in serum or plasma in patients with uremia [Fuchs et al 1988b]. 
Thus, in patients with impaired renal function accumulation of neopterin may occur in 
the blood that is in addition to the enhanced formation of neopterin by immune 
system activation. Calculating the neopterin per creatinine ratio is suitable to at least 





Neopterin and 7, 8-dihydroneopterin have a small molecular mass (253 and 
255 D), and are produced and released in a remarkably constant proportion with a 
ratio of aromatic neopterin to total (aromatic plus acid-oxidizable 7,8-
dihydroneopterin) neopterin of 1:3 for urine and arterial blood and 1:2 for serum 
obtained from venous blood samples [Murr et al 2002]. 
Since dihydroforms of pteridines are labile, collection and storage of samples 
is critical and problematic for large scale clinical handling. In daily clinical routine, 
advantageously only the more stable neopterin is quantified [Murr et al 2002]. 
Neopterin is sensitive to direct sunlight and irradiation and therefore samples must be 
protected from light during transport and storage prior to measurement of neopterin 
[Laich et al 2002]. The fresh samples that are collected could be protected e.g. by 
enveloping in aluminum foil, alternatively dark tubes may be used for collecting 
samples. An immediate transfer into dark freezer would be a logical step before 





Neopterin levels can be determined in various bodily fluids such as serum, 
plasma, CSF, and urine.  In serum, plasma and other protein-containing body fluids, 
e.g. cerebrospinal fluid, pancreatic juice or ascites, neopterin levels are preferably 
determined by immunoassays (ELISA or radioimmunoassay) [Mayersbach et al 
1994].  For the determination of neopterin in urine samples high pressure liquid 
chromatography (HPLC) on reversed phase is usually applied [Schroecksnadel et al 
2006].  Neopterin is detected by measurement of its natural fluorescence (excitation 
wavelength 353 nm, emission wavelength 438 nm), creatinine concentrations can be 
measured in parallel in the same chromatographic run by detection of its UV-
absorption at 235 nm wavelength. 
 
FIGURE 5. HPLCC apparatus and setup  [Waters.com] 
HPLC measurements of neopterin concentrations in serum or plasma are limited by 
the fact that protein precipitation will increase neopterin content of samples because 
of oxidation of its 7, 8-dihydroneopterin derivative [Werner et al 1987].  Thus, size-
exclusion filter cartridges or precipitation can achieve preanalytical separation of 
protein with non-acidic reagents such as acetonitrile [Flavall et al 2008]. No 










Table 1: Neopterin concentrations (mean ± S.D. and 97.5th percentiles) in urine of healthy 
individuals [neopterin.net] 
 
Neopterin in urine (µmol/mol creatinine): 
 
Age  Male  97.5 th Female 97.5th 
19-25 123+30 195 128+33 208 
26-35 101+33 182 124+33 209 
36-45 109+28 176 240+39 239 
46-55 105+36 197 147+32 229 
56-65 119+39 218 156+35 249 
>65 122+38 229 151+40 251 
 
 Normal values and upper limits of tolerance of urinary neopterin concentrations 
in healthy persons would change depending on age and sex, which is mainly due to 
variations of urinary creatinine concentrations [neopterin.net]. For example in a 
young person’s neopterin concentrations detected in the first morning urine are about 
1500 nmol/l, concentrations of creatinine about 12 mmol/l; thus, the normal value of 
healthy persons is calculated as about 125+5 µmol/mol creatinine. These variations 


















3. Background  
Neopterin in human pathology   
 Localized or systemic inflammation is a feature of a large proportion of human 
pathologies.  Recent investigations have also found links of inflammation to the 
development of cancer [Hagemann et al 2007, Laird et al 2011]. In fact inflammation 
is now labeled as one of the hallmarks of cancer [Colotta et al 2009]. A direct 
association of inflammation to some cancer like esophageal cancer with barrett’s 
oesophagus and inflammatory bowel disease with colorectal cancer is also well 
known.  
 A review points out that about 15% of the global cancer burden is attributable to 
infectious agents and inflammation is a major component of these chronic infections. 
Moreover, increased risk of malignancy is associated with the chronic inflammation 
caused by chemical and physical agents, and autoimmune and inflammatory reactions 
of uncertain aetiology [Balkwill and Mantovani 2001]. Chronic inflammation 
invariably leads to a chronic immune stimulation.   
Hence, the study of cytokines and biomarkers to monitor the immune activity 
can provide an insight in the processes involved in cancer development and can lead 
to new concepts and strategies for its management.  This activity of systemic 
inflammatory or immune response may be studied by measuring serum or plasma 
cytokine concentrations; however, cytokines are notorious for their marked 
fluctuations of systemic concentrations[ Melichar 2013].  It could therefore be argued 
that the measurement of stable biomarkers that could reflect the immune activity can 
be a logical alternative. 
Although in current practice biomarkers play an increasingly important role 
in the management of cancer patients, the utilization of biomarkers associated with 
host response to malignancy has been limited [Melichar 2013].  It is also worth 
noting that serial cytokine determinations for the longitudinal study of inflammatory 
phenomena and the measurement of routine markers of inflammation such as CRP 
and other acute phase reactants require venipuncture, which is not only 
uncomfortable for the patients but also has potential complications in addition to the 
administrative and cost implications.  Hence, there is a place for a compound that 






Neopterin and chronic immune stimulation  
 
As described earlier, neopterin is produced from GTP by macrophages upon 
activation of GCH-1 by INF gamma, which is a cytokine produced by T-lymphocytes 
and natural killer cells.  Because the production of IFN- gamma is enhanced by pro-
inflammatory cytokines such as interleukin-1 or interleukin-6, systemic 
concentrations of neopterin accompany both systemic immune and inflammatory 
response [Wachter et al 1989].  
 The general state of immune activation in patients with advanced cancer, 
evidenced by increased neopterin production and increased expression of lymphocyte 
activation markers like CD69 or HLA-DR, may be a consequence of the failure of the 
host immune system to cope with the tumor [Melichar et al 2006a]. We know from 
studies that chronic immune stimulation in cancer patients is associated with 
alterations in leukocyte phenotype and function [Melichar et al 2006a]. In addition, 7, 
8-dihydroneopterin has been shown to induce apoptosis in freshly isolated human T-
lymphocytes in a concentration-dependent manner [Baier-Bitterlich et al 1995].  Thus 
chronic immune activation may lead to a qualitative and quantitative impairment of 
the host defense that would be responsible hampering adequate immune response.  
The net result of these complex immune activities would again influence the 
levels of neopterin that can be easily observed by analyzing the urine of the patient. 
 
Neopterin and prognosis in cancer patients  
 
 Neopterin has been of particular interest in oncology.  There have been studies 
linking neopterin to diagnosis and prognosis of the underlying malignant disease. 
          It has been demonstrated that the sensitivity of the urine neopterin in diagnosis 
varies according to the type and stage of cancer [Bayram et al 2004]. Reports suggest 
that this sensitivity reaches almost 100% accuracy in cases of hematologic neoplastic 
condition (non-Hodgkin’s lymphoma, chronic lymphoblastic leukemia) [Abate et al 
1989].  On the other hand the data for different solid tumor was found to be variable.  
The frequency of increased neopterin in other cancers such as gynecologic cancers 





cancers of colon ranges over 50% [Putzki et al 1987]. However, the sensitivity in 
breast cancer has been found to be much lower at around 20% [Wiegele et al 1984]. 
 Studies in patients with hematological malignancies revealed that neopterin 
concentrations correlate with tumor stage of non-Hodgkin and Hodgkin lymphomas 
and might be considered as a prognostic marker [Hausen et al 1981, Piccinini et al 
1991].  In patients with multiple myeloma neopterin concentrations were found to be 
more predictive of prognosis than interleukin-6 (IL-6) [Reibnegger et al 1991].  
 Though the sensitivity in patients of breast cancer was low, an increased urinary 
neopterin excretion was found to be a sign of poor prognosis attributed to either   
disease progression or events leading to death [Reibnegger et al 1987, Murr et al 2002 
and Melichar et al 2006a] 
 Yildirim et al. suggest that neopterin seems to be an indicator of metastatic 
cancer rather than a marker for local cancer [Yildrim et al 2008].  A review of 
literature would reveal that increased urinary and serum neopterin concentrations 
have been reported in patients with gynecological cancer, including epithelial ovarian 
carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcomas and vulvar 
carcinoma [Melichar et al 2006a], colorectal cancer, liver tumors and breast cancer. In 
all tumor entities a highly significant association was found between neopterin 
concentrations and the risk for relapse, metastases or death. High neopterin levels 














Table 2: Depictions of evidence in literature on tumor types and the use of neopterin 














Uterine sarcoma! 78! -!
Multiple Myeloma! 30-70! yes!
Pancreatic carcinoma! 69! yes!
Lung cancer! 58! yes!






Colon cancer ! 48! yes!
Cervical carcinoma ! 55! yes!
Stomach carcinoma! 42! yes!
Prostatic carcinoma ! 25! yes!
Malignant melanoma! Below 25! -!
Breast carcinoma! 18-25! yes!











Anticancer therapy, immune activation and neopterin    
The effect of anticancer therapy on immune system and potential of 
immunomodulation in anticancer therapy has been a topic of interest for the oncology 
community. Several studies have described effects of cytotoxic drugs on 
macrophages, dendritic cells (DCs) and natural killer (NK) cells.  In their experiments 
with rodents, Ghiringhelli et al. have shown that oral administration of metronomic 
(low dose) cyclophosphamide in advanced cancer induces a profound and selective 
reduction of circulating regulatory T cells, associated with a suppression of their 
inhibitory functions on conventional T cells and NK cells leading to a restoration of 
peripheral T cell proliferation and innate killing activities [Ghiringhelli et al 2007].  In 
another study cyclophosphamide increased the frequency of tumor-infiltrating CD4 
and CD8 cells containing interferon gamma, NK, dendritic cells, with the greatest 
increases seen among tumor-infiltrating lymphoid cells (TIL) in mice tumors [Pu et al 
2010]. Another chemotherapeutic agent 5-FU in conjunction with IFN-a was found to 
enhance the NK mediated cytotoxicity [Khallouf et al 2012].   
There is evidence that chemotherapy has an effect on macrophages too. Again 
cyclophosphamide metabolites were found to increase the tissue associated 
macrophages (TAM-M1) that enhance the production of proinflamatory Il-6, IL-12 
and oxygen radicals, and thus can significantly increase the specific immune response 
as well as nonspecific innate reaction [Brynarski et al 2009]. Paclitaxel can not only 
stimulate TAMs cytotoxicity directly [Park et al 2013] but also induce the activation 
of dendritic cells (DCs), NK and tumor-specific CTL via the secretion of IL-12, TNF-
a and inducible nitric oxide synthase (iNOS) by TAMs, [Javeed et al 2009] resulting 
in tumor regression [Bracci et al 2014]. 
In addition, there have been studies depicting a direct immunomodulatory 
effect of chemotherapy. In an unbiased functional screen of 54 chemotherapeutic 
agents, Tanaka et al. unveiled the diversity of the tested drugs on the maturation, 
survival and growth of DCs [Tanaka et al 2009]. The drugs delivering DC maturation 
signals at concentrations causing only marginal DC death included topoisomerase 
inhibitors (for example, etoposide, mitoxantrone, doxorubicin), antimicrotubule 
agents (for example, vinblastine, paclitaxel, docetaxel) and the two alkylating agents 





macrophages the authors were able to demonstrate that in low noncytotoxic 
concentrations chemotherapeutic agents do not induce apoptosis of DCs, but directly 
enhance DC maturation and function [Kaneno et al 2009]. In another report, 
paclitaxel, doxorubicin and methotrexate were shown to promote the ability of murine 
BM–DCs to present antigens to T-cells in vitro by upregulating antigen-processing 
machinery gene components, costimulatory molecules and IL-12 [Shurin et al 2009]. 
In an interesting study it was shown that 5-FU and doxorubicin could induce 
in vitro cancer expression of heat shock proteins (HSPs) and thereby promote the 
engulfment of cell debris by human DCs and the subsequent cross- presentation of 
tumor antigens to T-cells [Bracci et al 2014, Buttiglieri et al 2003]. Thus, it could be 
argued that the changes in the neopterin levels could reflect the complex 
immunological play being staged in the system of a patient suffering from malignancy 
whilst they are on treatment.  
Similar to cytotoxic chemotherapy, radiation is known to cause direct tumor 
damage by the DNA breakdown and by affecting various intracellular process. The 
net effect is cancer cell death and tumor control.  In addition to the direct effect on 
cancer cells, radiation has also been shown to affect the neopterin levels [Holečková 
et al 2013] and thus reflect changes in immune system. A study was able to 
demonstrate that α irradiation can stimulate adaptive immunity, can elicit an efficient 
antitumor protection, and therefore could be an immunogenic cell death inducer [ 
Gorin et al 2014]. In another study dealing with the impact of high-dose ablative 
radiotherapy (RT) on tumor microenvironment components, the high dose ablative 
RT given to the tumor was found to induce bystander/abscopal factors and endothelial 
cell death coupled with immune activation [Prassanna et al 2014]. Various researchers 
have tried to use the effects of RT on the immune system for immunotherapy. Witek 
et al. have argued that optimal sequencing of RT and immunotherapy amplifies 
antigen-specific local and systemic immune responses, revealing novel acute and 
long-term therapeutic antitumor protection [Witek et al 2014]. In an observation it 
was found that whereas high doses of radiation (>10 Gy) can lead to lymphopenia, 
lower radiation doses (2-4 Gy) represent a valid treatment option in some 
hematological cancers and it triggered clinically relevant immunological changes. In 





induced by synergistic radiation treatment with potential physiological significance in 
a wide range of T cell responses [Spary et al 2014]. Again, monitoring the neopterin 
levels may reflect these radiotherapy induced immune changes.  
Though we have significant data on neopterin and conventional anticancer 
treatment, the information of neopterin and targeted biological therapy is limited.  In 
modern oncology practice biological therapy is increasingly playing a crucial role in 
management of various tumor types leading to an improved treatment outcome. 
However, not all patients benefit equally from similar biological therapy and the 
precise mechanisms by which the targeted agent such as cetuximab act appear to be 
more complex than previously thought.  
A good example can be the finding that the EGFR targeted drug did not 
benefit all patients and it was later revealed that it was due to the KRAS status of the 
patient.    The analysis of pooled data from the CRYSTAL and OPUS studies 
confirms the consistency of the benefit obtained across all efficacy end-points from 
adding cetuximab to first-line chemotherapy in patients with KRAS wild-type 
metastatic colorectal cancer [Bokemeyer et al 2012]. However, activity had also been 
demonstrated for cetuximab in combination with chemotherapy in the first line of 
treatment of metastatic colorectal carcinoma in patients with tumors not harboring 
RAS mutation [Bokemeyer et al 2009, Van Cutsem et al 2009]. Thus, underlining 
alternative mechanism of action of this agent.   With such information the precise 
mechanism of anti-tumor activity of cetuximab is still being explored.  Similar to 
cetuximab, most of targeted drugs may inhibit tumor growth through more than one 
mechanism acting on multiple molecular targets.  Among proposed mechanisms of 
biological agents, the activation of the host immune response has also been implicated 
[Messersmith et al 2007, Zhang et al 2007].  
In a study of patients of lung cancer it was found that in vivo antitumor 
activity of cetuximab could be associated with a complement-mediated immune 
response.  In the same study Hsu et al. emphasized the need to elucidate the molecular 
mechanisms involved in cetuximab activity in order to improve its clinical efficacy 
and to better select patients who would benefit from cetuximab treatment [Hsu et al 
2010]. In a recent article it was proposed that cetuximab can inhibit tumor growth by 





(ADCC), which not only suppresses tumor growth but also triggers innate immunity 
to improve CTL cross-priming by DC. This enhanced CTL response, in turn, can then 
kill more tumor cells to create a positive loop that initiates danger/innate signaling 
that further generates both innate and adaptive immunity against the tumor, and 
ultimately leads to tumor regression [ Xuanming et al 2013].  
Collectively, these studies provide insight into a novel antitumor mechanism 
of anti-EGFR Ab therapy that promotes cooperation between innate and adaptive 
immunity and warrants reconsideration of the adaptive immune system in current 
therapy regimens and antitumor therapy design [Xuanming et al 2013]. Moreover, as 
presented in a review, anticancer drugs such as fluorouracil and gemcitabine 
administered prior to mAb administration could induce antigen reediting (induction of 
neoantigens and/or upregulation of pre-existing antigens) in cancer cells and activate 
powerful danger signals (i.e., HSP-90 and calreticuline). Once opsonized and/or 
phagocytosed by DCs and macrophages these cells could become a great source of 
neoantigens available for an efficient antigen-specific T-cell response with long-term 
memory [Correale et al 2011]. 




 FIGURE 6: The proposed immune modulatory mechanism of targeted agent (cetuximab) 






The immunological activity associated with administration of biological 
agents will be a matter of great interest with the advent of newer immunomodulatory 
drugs. Based on the above evidence it could be argued that the biomarkers of immune 
activity can play a vital role in monitoring the response to therapy. It can also provide 
more information in the pursuit to explain the anti-cancer mechanism of targeted 
therapy.   Neopterin by virtue of reflecting systemic immune activation could be an 
important tool to investigate not only mechanism of action of biological agents but 
could also help in identifying the subtypes with varying degree of response. 
 The levels of neopterin are also linked to several other parameters that may 
directly influence carcinogenesis, response to treatment and even complication in 
cancer patients. The association of several clinical and laboratory parameters with 
neopterin has been proven by both laboratory and clinical studies.   A review of some 
major factors can provide an insight into the potential use of measuring neopterin 
levels in cancer patients.   
 
Neopterin and weight-loss and cachexia 
 
 Clinically the presence of cachexia has been shown to be a significant risk 
factor and an indicator of negative prognosis in cancer patients [Ramos et al 2004]. 
Unfortunately, there is a dearth of strong evidence based management strategy for 
cancer related cachexia. Cachexia is essentially a catabolic state that is mediated by 
multiple factors. Factors like TNF-alpha {cachectin} and IFN- gamma may work 
individually or in conjunction leading to the breakdown of the tissues [Moldawer et al 
1997].   Kurzrock has highlighted the roles of different interleukins in addition to 
TNF, IFN-gamma, and leukemia inhibitory factor acting as cachectins in animal 
models [Kurzrock et al 2001]. 
 In their study with patients with HIV infection Zangerle et al found weight loss 
of more than 10% of body weight is associated with immune activation [Zangerle et 
al 1993 ]. They observed a correlation between body mass index, urinary neopterin 
and CD4+ T-cell count, development of AIDS-defining infections, weight loss, and a 
decline in CD4+ T-cell [Zangerle et al 1993]. Extrapolating from their result one 
could hypothesize that the neopterin levels can reflect the pro inflammatory states in 





of cancer cachexia and other complications. Serial monitoring of neopterin levels in 
cancer patients could potentially forewarn clinician of processes leading to this 
complication.  In future a better understanding of the biochemistry of cachexia could 
provide more insight into development of this complication and we may be able to 
adopt measures to prevent and treat this symptom and improve the quality of life of 
the patients.  
 
Neopterin and Anemia 
 Anemia is a common finding in cancer patients and a correction of anemia plays 
a vital role for optimal treatment outcome. Neopterin levels were found to be elevated 
in cancer related anemia [Fuith et al 1989, Weiss et al 2004] and an inverse 
correlation of the urinary neopterin levels with hemoglobin levels has been in found 
patients  [Fuith et al 1989, Denz et al 1992].  
Further studies corroborated the early findings of a negative correlation 
between urinary neopterin and hemoglobin, hematocrit, serum iron, iron-binding 
capacity, and transferrin saturation indexes whereas a positive correlation was 
observed between urinary neopterin and serum ferritin and erythropoietin levels [Ji et 
al 2012]. These results implicate the systemic immune activation, reflected in 
increased neopterin production, in the pathogenesis of anemia in patients with cancer 
[Melichar et al 2006a].  
 
Neopterin, depression and fatigue 
 
  Patients with malignant disease can present with profound fatigue, severe mood 
changes and depression. Enhanced neopterin production leads to deficient BH4, 
which is critically involved in the biosynthesis of biogenic amines including serotonin 
and several adrenergic/dopaminergic neurotransmitters [Neurauter et al 2008]. Thus 
neopterin may reflect the immune mechanism of various cancer related 
neuropsychiatric symptom. For example increase in urinary neopterin levels were 
found to precede increase in fatigue intensity with a temporal delay of 60—72 hours 








Potential use of neopterin in detecting complications 
 
Neopterin can also reflect the systemic immune and inflammatory responses 
in various other human disorders.     A review of literature reveals that neopterin has 
been employed to study a range of pathologies.   
Studies on patients with clinical evidence of infection and related reviews 
have tried to highlight the utility of neopterin in these cases [Cesur et al 2005].  For 
example neopterin has been investigated for use in monitoring sepsis and tuberculosis 
[Turgut et al 2006, Berdowska et al 2001]. Neopterin levels have also been shown to 
have meaningful trends in HIV infection [Melichar et al 2006a], parasitic infection 
[Berdowska et al 2001] and other exotic infections [Handan et al 2005].  In addition 
to reflecting the disease states neopterin has also been employed to monitor disease 
process and response to treatment. For example, some findings suggest that the 
pretreatment level of neopterin might be used in routine clinical practice as rapid and 
cost-effective marker to predict the response to antiviral therapy in HCV patients 
[Oxenkurg et al 2012]. Neopterin measurements were also useful to monitor therapy 
in patients with HIV infection [Murr et al 2002]. 
In addition, neopterin has also been used to monitor therapy in autoimmune 
disorders. It has been suggested that determination of tryptophan degradation and 
neopterin levels in chronic inflammatory disease may provide a better understanding 
of progression of these diseases [Ozkan et al 2012].  
Neopterin has also garnered interest from workers studying ageing as it is also 
supposed to represent a characteristic of ageing. Immune deviations that are most 
widely expressed in the elderly include increased neopterin production and tryptophan 
breakdown. Increases in neopterin were found to correlate with a substantial decline 
in key vitamins, including folate and vitamin-B6, -B12, -C, -D and -E. [Capuron et al 
2014].  Interestingly, a correlation between baseline parameters of intestinal 
permeability and urinary neopterin has also been observed [Dvorak et al 2010]. 
A remarkable use of neopterin has been made in investigations of acute 
medical conditions too.  Schumacher et al. study produced data to support the 
hypothesis of an activation of monocytes and macrophages in patients with an acute 





increased in patients with chronic coronary artery disease and more pronounced in 
patients with acute myocardial infarction shortly after the onset of symptoms 
[Schumacher et al 1997]. A prospective study suggested that determinations of 
neopterin and IL-18 concentrations might represent early markers for post-traumatic 
complications such as multiple-organ dysfunction syndrome and sepsis [Mommsen et 
al 2009].  
There are several other noteworthy studies that emphasize the relevance of 
neopterin in clinical investigations. For example screening of neopterin 
concentrations in blood donations allows detection of acute infections in a non-
specific way and improves safety of blood transfusions [Murr et al 2002]. In a study 
on patients with kidney transplant by Carey et al, higher neopterin levels were 
correlated with acute rejection in the first year post-transplant, but this was only 
significant in recipients who received kidneys from donors after cardiac death, and 
who suffered acute cellular or vascular rejection [Carey et al 2013].  
Neopterin in therapy related complications 
 
Not only was neopterin found to depict the immune activation due to therapy 
but due to its peculiarity it also rose in other inflammatory condition including the 
complications that frequently occur in cancer patients.  An association of 
complications and higher levels of neopterin have been documented and urinary 
neopterin concentrations were found to be relatively stable in cancer patients in the 
absence of complications [Melichar et al 2007a].  Significantly higher neopterin 
levels were noted in patients with two or more comorbid conditions.  Data by 
Melicharova et al. has demonstrated an association between systemic immune 
activation, reflected in increased urinary neopterin concentrations, and age or 
presence of comorbid diseases in patients with breast carcinoma.  A cumulative effect 
was observed with the presence of two or more comorbid conditions resulting in 
significantly increased urinary neopterin [Melicharova et al 2010] 
In a noteworthy study on patients of head and neck tumors neopterin level was 
significantly increased following the changes of the intensity of nausea, vomiting, 
mucositis, skin toxicity, xerostomia, laryngeal toxicity, pharyngeal toxicity, upper 





neopterin that resulted from changes of toxicity were delayed by lag times ranging 
from 5 to 24 days. The strongest effect on neopterin concentrations was observed for 
nausea, mucositis and performance status [Holečková et al 2013]. Administration of 
anticancer therapy induces an inflammatory response. Changes in physiology 
associated with systemic inflammatory response, including metabolism of trace 
elements and vitamins, may play an important role in the toxicity of combined-
modality treatment [Holečková 2013].   In addition, earlier in section on neopterin in 
human pathology, we have seen the association of neopterin in non-malignant 
condition, too. Thus, the ability of neopterin to reflect the immune outcome of variety 
of clinically relevant conditions can potentially be utilized in monitoring complication 
in cancer patients.  
Thus one could argue that neopterin being a marker of immune activation, 
could possibly be used in clinical settings to monitor immune activity in cancer 
patients. Immune activity may be responsible for overall outcome, response to 
treatment and my even reflect the complication.  With the background of above 
evidence we sought to test the potential use of neopterin in prognosis, monitoring 

















4. Objective   
 
Based on the available evidence we hypothesized that neopterin has the 
potential to be of use in routine oncology practice specifically in the assessment of 
prognosis, monitoring response to therapy and complications in cancer patients.  
To test the hypothesis a project was designed to investigate specific aspects 
mentioned above.  The project addressed the associations of neopterin and the 
following clinically relevant issues. 
1. The changes in neopterin levels during anticancer therapy including 
chemotherapy, biological therapy and radiotherapy.  
2. Utility of neopterin in predicting prognosis  
3. Correlation of neopterin with various laboratory parameters  
4. The correlation of neopterin and complications in patients undergoing 




















Venue   
The study was mainly performed at the University Hospital in Hradec Kralove. 
The patients being treated at the department on oncology and radiotherapy were 
recruited for the study. 
 
 
Department of Oncology and Radiotherapy  












5. Study design  
Our project was divided in two parts 
Part I 
To analyze urine samples in patients to investigate if neopterin levels could be used in 
prognosis and monitoring response to systemic and biological therapy. 
 
Part II 
To analyze the urinary neopterin in patients during chemo-radiotherapy and to 
investigate association of neopterin to complications 
 
For the purpose of our study, different cohorts of patients were recruited:  
1. Cohort A- Patients of Metastatic colorectal carcinoma undergoing systemic 
treatment, n=45 
2. Cohort B -Patients with Gynecological malignancy undergoing pelvic 
radiotherapy with concomitant chemotherapy, n=10 
The total number of patients in whom urinary neopterin was studied was 55. 
The individual patient groups, characteristics, methodology and results relevant to the 
study parts are described separately.     
Sets of patients and statistical analysis  
The investigations were carried out at the University Hospital in Hradec 
Kralove.  The patients were enrolled at the Department of Oncology and 
Radiotherapy and the sample were stored in the specially assigned refrigerators in the 
Department of Oncology and also at the Department of Pathology.  
The determination of urinary neopterin was performed in the laboratory of the Third Department of 







In the following sections we present: 
• Patient characteristics in all patient groups 
• Methodology 
• Statistics  
• Results  





















6. Study  
6.1 Part I 
6.1.1 Patient group- Cohort A 
The patient group was selected from the patients being treated at the University 
Hospital in Hradec Kralove  
 
Diagnosis of patients in cohort A  
Metastatic colorectal carcinoma !
Patient characteristics  
• Number of Patients = 45 
• Male 28 
• Female 17 
• Aged (mean±standard deviation) 60±11 (range 32–78)  
Anticancer therapy in patients of cohort A 
43 Patient – Treated with  
Cetuximab (loading dose 400 mg/m2, subsequently 250 mg/m2 weekly) followed by 
irinotecan (180 mg/m2), leucovorin (200 mg/m2), and 5-fluorouracil (400 mg/m2 
bolus and 1200 mg/m2 for 46 hours) .  The regimen was administered two weekly.  
1 Patient – treated with  
Cetuximab (loading dose 400 mg/m2, subsequently 250 mg/m2 weekly) followed by 
irinotecan (180 mg/m2), leucovorin (200 mg/m2), and 5-fluorouracil (400 mg/m2 
bolus and 1200 mg/m2 for 46 hours) . The regimen was administered two weekly with 
modification. ( Irinotecan was omitted due to hypebilirubinemia)  






Summary of patient group A 
 
Forty-five consecutive patients with metastatic colorectal carcinoma, 28 males 
and 17 females, aged (mean±standard deviation) 60±11 (range 32–78) years were 
included in the study. Forty-three patients were treated with the combination of 
cetuximab (loading dose 400 mg/m2, subsequently 250 mg/m2 weekly) followed by 
irinotecan (180 mg/m2), leucovorin (200 mg/m2), and 5-fluorouracil (400 mg/m2 
bolus and 1200 mg/m2 for 46 hours) every two weeks (including one patient who 
received a modification of this regimen). One patient with hyperbilirubinemia had 
been treated with the above regimen omitting irinotecan, and one patient was treated 
with cetuximab monotherapy. All patients had been previously treated with 
oxaliplatin, and all but one patient had been pre-treated with an irinotecan-containing 
regimen.  
 
6.1.2 Methodology  
All patients were being treated at the Department of Oncology and 
Radiotherapy at the University Hospital in Hradec Kralove.  
The investigations were part of a project approved by the institutional ethics 
committee and the patients signed informed consent. After consenting, a collection of 
urinary samples was initiated in all patients.  
 Early morning urine specimens were collected for each patient before and 
during the course of anticancer therapy. The first sample was always before the start 
of treatment. A sterile collection dish was given to the patient and sample was 
collected from the dish to a sterile urine vial. The sample were labeled and 
numbered. These vials were immediately transferred into a refrigerator. A 
temperature of -20o C was maintained throughout.  The entire batches of samples of 
each patient were serially collected in a separate box until analysis. 
The determination of urinary neopterin was performed in the laboratory of the Third  









Sample preparation  
 
The samples were gradually thawed from their frozen state. After a brief 
centrifugation for 45 second at 12000 x g, 100 ml of urine samples were diluted with 
1.0 ml of mobile phase containing disodium-EDTA (2 g per liter), the samples were 
filtered using Microtiter, AcroPrep 96 Filter Plate 0.2 µm/ 350 µL, Pall Life Science 
(Ann Arbor, MI, USA) and Vacuum manifold Pall Life Science and then injected 
into a column.  
Neopterin was determined using high performance liquid chromatography 
system Prominence LC20 (Shimadzu, Kyoto, Japan) composed from Rack changer/C 
- special autosampler for micro titration plates, Degasser DGU-20A5, 2 Liquid 
chromatograph Pumps LC-20 AB, Auto sampler SIL-20 AC, Column Oven CTO – 
20 AC Thermostat, Fluorescence detector RF- 10 AXL, Diode array detector SPD – 
M20A and communications bus module CBM-20A. Phosphate buffer 15 mmol/L, 
pH 6.4 with flow rate 0.8 mL/min was used as mobile phase. Separation was 
performed using hybrid analytical column Gemini Twin 5µ, C18, 150 × 3 mm 
(Phenomenex, Torrance, CA, USA) at 25°C, injection volume was 1µL. Neopterin 
was identified by its native fluorescence (353 nm excitation, 438 nm emission!
wavelength).  
Creatinine was monitored simultaneously in the same urine specimen with 
diode array detector at 235 nm. Time of analysis for urine neopterin and creatinine 
was 6 minutes and the analytes were quantified by external standard calibration. The 
neopterin concentrations were expressed as neopterin/creatinine ratio (µmol/mol 
creatinine). 
Hemoglobin was measured by a photometric method using sodium lauryl 
sulfate, leukocytes and platelets were determined by impedance method using a 
Sysmex XE-2100 blood analyzer (Sysmex, Kobe, Japan).  
Differential leukocyte count was obtained.  
Serum carcinoembryonic antigen (CEA) was determined by 









Neopterin cut off  
Normal values and upper limits of tolerance of urinary neopterin 
concentrations in healthy persons would change depending on age and sex which is 
mainly due to variations of urinary creatinine concentrations [neopterin.net]. These 
variations need to be accounted for when performing study like ours. In our study 
neopterin levels of 214 (μmol/mol creatinine) was chosen cut off between two 
groups.  This was also found to be upper limit of normal in pervious study by our 
group [Melichar et al 2008b] and was selected based on medians of respective 
parameters in the studied group. 
 
 
Cohort A samples 
 
FIGURE 7. Number of serial samples collected in Part 1 of the study with patients in Group A. 




































































































6.1.3 Statistical tests used  
 
The statistical analysis of the data was performed using NCSS software 
(Number Cruncher Statistical Systems, Kaysville, Utah, USA). 
 
The following tests were employed  
 
Differences during therapy were evaluated using the Wilcoxon paired test.  
 
Correlations were examined using Spearman's rank correlation coefficient.  
 
Survival was analyzed using the Kaplan-Meier method, and differences were 
evaluated by log-rank test.  
 




6.1. 4 Results  
Pretreatment urinary sample was collected in 45 patients 
The serial urine collection was completed in 36 patients. 
The patients were divided into two groups:  
1. Those with initial urinary neopterin concentration of 214 [µmol/mol creatinine] 
or above 







FIGURE 8. Patients of cohort A in whom serial urinary samples were collected were divided in 
two groups based on High and Low Neopterin/Creatinine ratio (214 as the cut off) are shown in 
Figure 8 
 
























































































TABLE 3 .The mean ± standard deviation of neopterin levels in the two groups  a p < 0.05, b p 
< 0.01, c p < 0.001, d p < 0.0001. The standard deviations of neopterin in high and low 














FIGURE 9. The changes in urinary neopterin concentrations during the course of therapy in 
patients 1-6 of cohort A are shown in Figure 9 
 
 
FIGURE 10.  The changes in urinary neopterin concentrations during the course of therapy 





































FIGURE 11. The changes in urinary neopterin concentrations during the course of therapy in 
patients13-18 of cohort A are shown in Figure 11. 
 
FIGURE 12.  The changes in urinary neopterin concentrations during the course of therapy 




































FIGURE 13. The changes in urinary neopterin concentrations during the course of therapy in 
patients 25-30 of cohort A are shown in Figure 13. 
 
 
FIGURE 14. The changes in urinary neopterin concentrations during the course of therapy in 






































FIGURE 15.  
The course of urinary neopterin concentrations during the course of therapy in a 78-year-old 




































FIGURE 16. Stacked line graph showing trends in patients with Neopterin/ Creatinine < 214 
(µmol/mol!creatinine)!in Group A.  The stacked lines showing trend of changes in urinary 
neopterin levels in patients with pretreatment neopterin <214 (µmol/mol!creatinine)!are 












































FIGURE 17. Stacked line graph showing trends in patients with Neopterin/ Creatinine ≥214 
(µmol/mol!creatinine) in Group A. The stacked lines showing trend of changes in urinary 
neopterin levels in patients with pretreatment neopterin ≥214 (µmol/mol!creatinine)! are 






































FIGURE 18. Correlation between urinary neopterin and hemoglobin in patients of group A 
 
The negative correlation between hemoglobin and urinary neopterin concentrations (rs 



















FIGURE 19. Correlation between peripheral blood leukocyte count and urinary neopterin 
concentrations in patients of group A 
 
 
The correlation between urinary neopterin and peripheral blood leukocyte count (rs = 






















FIGURE 20. Correlation between carcinoembryonic antigen and urinary neopterin 
concentrations  
 
The correlation between serum carcinoembryonic antigen (CEA) and urinary 


















FIGURE 21. Survival curves cohort A 
At the time of the analysis, 44 patients died while one patient was alive after 74 months. 
Survival of patients with urinary neopterin concentration of 214 [µmol/mol creatinine ] or 
above was significantly inferior compared to patients with initial urinary neopterin below 
















Cohort A = Metastatic colorectal carcinoma 
Table 4a 
Day N Mean Median Minimum Maximum Std. Deviation 
1 36 251 186 10 1279 232.384 
2 33 246 214 69 707 146.501 
3 36 276 266 110 915 154.888 
4 35 293 292 85 813 145.139 
5 35 293 243 94 911 153.320 
6 34 277 216 93 843 158.300 
7 25 239 199 83 786 147.054 
8 33 257 202 91 986 182.854 
9 30 272 206 79 1025 207.839 
10 30 262 240 78 853 150.483 
11 29 242 229 72 635 129.842 
12 31 260 200 69 946 174.018 
13 30 265 211 87 970 186.021 
14 27 271 249 106 914 167.414 
15 28 323 233 101 1876 332.719 
16 27 255 188 122 1031 218.205 
17 31 248 199 91 1110 183.827 
18 31 313 243 99 2040 364.039 
19 31 239 193 92 873 144.442 
20 31 271 234 94 1320 220.741 
21 27 235 191 37 863 154.604 
22 25 259 200 70 922 172.548 
23 27 265 204 101 1087 193.473 
24 25 261 206 96 1177 212.697 
25 26 236 193 100 831 146.858 
26 26 238 196 82 669 119.428 
27 25 229 206 99 788 141.517 
28 19 258 204 119 684 135.629 
29 18 250 222 0 660 149.821 
30 11 282 245 52 540 158.928 
31 12 239 205 131 557 114.164 
32 12 260 243 122 523 125.643 
33 12 267 262 101 574 126.124 
34 11 334 212 108 1040 272.916 
35 12 238 185 122 503 119.111 
36 11 467 212 125 2839 794.343 
38 19 314 248 123 591 146.314 
39 10 300 298 149 506 123.224 
40 10 279 283 119 436 99.892 
41 9 442 271 126 1686 479.919 
42 9 297 300 136 498 125.536 
43 8 293 289 152 424 103.372 
44 5 278 349 83 423 151.728 
45 5 335 383 155 469 134.659 
46 5 325 396 143 423 125.949 
47 5 332 356 138 494 158.665 
48 5 380 410 237 517 124.357 
49 5 306 360 174 427 108.544 
50 4 380 433 202 452 120.120 
51 4 521 414 277 981 313.882 
52 3 371 440 213 460 137.179 
53 3 283 213 196 440 136.090 
54 3 369 320 253 533 146.219 
55 3 399 488 172 537 198.064 
56 3 401 465 164 573 212.089 
57 3 442 566 162 598 242.864 
58 2 275 275 65 486 297.924 
59 2 430 430 172 689 365.437 
60 2 380 380 151 608 323.031 
61 2 451 451 183 719 379.060 
62 2 483 483 174 792 436.963 
Total 1053 275 221 0 2839 204.003 
 










 1 170 
 2 180 
 3 183 
 4 208 
 5 352 
 6 437 
 7 485 
 8 571 
 9 617 
 
Table  4b : Pre-treatment Neopterin in patients in whom serial sample collections could not 
be completed  
&
The table 4a depicts the mean ± standard deviation (SD) of interval between the 
treatment start and sample collection, number of patients examined, mean ± SD of 

























Summary of results of part I 
 The mean (±standard deviation) of urinary neopterin at baseline was 272±225 
µmol/mol Creatinine. A significant correlation was observed between urinary 
neopterin and peripheral blood leukocyte count (rs=0.38; p<0.05; Figure 19), 
hemoglobin (rs= -0.34; p<0.05; Figure 18) and CEA (rs=0.33; p<0.05; Figure 20) 
concentrations. Seventeen patients had urinary neopterin ≥214 µmol/mol creatinine. 
Daily neopterin measurements were obtained from 36 patients (Figures 9- 
15). The mean number of measurements obtained was 21±18 (range 1-58). Two 
fundamental patterns of urinary neopterin were evident based on initial neopterin 
concentrations. In patients with pre-treatment urinary neopterin ≥214 µmol/mol 
creatinine, a stable or decreasing pattern of urinary neopterin concentrations was 
usually observed. In contrast, urinary neopterin increased significantly in patients 
with initial neopterin <214 µmol/mol creatinine (Figure 16, 17) . In the patient 
treated with single-agent cetuximab, an increase of urinary neopterin was observed 
despite elevated initial neopterin concentrations (Figure 15). 
At the time of the analysis, 44 patients died while one patient was alive after 
74 months. Survival of patients with urinary neopterin concentration of 214 
µmol/mol creatinine or above was significantly inferior compared to patients with 
initial urinary neopterin below 214 µmol/mol creatinine (median 10.1 vs. 17.7 














6.2 Part II 
6.2.1 Patient group - Cohort B 
Patient group 
The cohort B of patients was selected from the patients undergoing treatment for 
gynecological malignancies at the department of oncology and radiotherapy at 
University Hospital in Hradec Kralove.  
Rationale for selection of cohort B 
a. Patients with carcinoma of cervix undergo a short course high intensity 
treatment that includes chemotherapy and radiotherapy. 
b. Cisplatin can cause significant toxicity and complication. 
a. Significant doses of radiation are delivered in pelvic radiotherapy.  
b. As a first step it would be sensible to monitor acute complications during the 
short course of intense treatment. 
c. Since the patients spent majority of time in hospital during treatment, serial 
sample collection was logistically easier!
Part II 
Number of patients, n = 10 
Diagnosis -   
1. Patients with carcinoma of uterine cervix, n = 9 
















Table 5. The cohort of patients studied in cohort B. Age group, histology and staging  
 
Patient Age (years) Histology FIGO stage 
1 50 Adenoc. III.B 
2 51 Adenoc. II.B 
3 60 Adenoc. III.B 
4 42 SCC III.B 
5 49 Adenoc. II.B 
6 36 SCC III.B 
7 70 Adenoc. III.B 
8 45 SCC II.B 
9 49 SCC III.B 





 FIGURE 22  - Staging of patients in cohort B . The division of patients in cohort B 

















Treatment given to the patients in cohort B 
1. Patients with carcinoma of the uterine cervix n= 9  
Treatment – Underwent radiotherapy at doses of 50 Gy in 25 fractions. 
All patients were treated with concomitant weekly Cisplatin (40mg/m2)  
2. Patient with carcinoma of the vulva  n=1  
Treatment – Underwent radiotherapy alone  
 
Summary of patient group B 
 
 Nine patients with carcinoma of the uterine cervix and one patient with 
carcinoma of the vulva treated with pelvic radiotherapy were included in the present 
analysis (Table 5).  
Patients were staged according the Fédération Internationale de Gynécologie 
et d'Obstétrique  (FIGO) classification [Quinn, 2006].  
All patients with cervical carcinoma were treated with concomitant weekly 
cisplatin (40 mg/m2) while the patient treated for carcinoma of the vulva received 
radiotherapy alone. 
Patients with carcinoma of the uterine cervix were treated with whole pelvis 
three-dimensional conformal radiotherapy using a linear accelerator with 18 MV 
photons. Dose was prescribed at the ICRU (International Commission on Radiation 
Units and Measurement) point and was 50 Gy in 25 fractions (2 Gy per fraction). In 
patients with cervical cancer, treated with intracavitary high dose rate brachytherapy, 
the dose was prescribed to a selected reference point “A” (defined as a point 2 cm 
lateral to the cervical canal and 2 cm superior to the ovoids.) Dose for organs at risk 
is reported using individual points for the bladder and rectum. Patients underwent 6 
fractions of brachytherapy, 4 Gy per fraction, three fractions per week. The dose in 
the patient with recurrent carcinoma of the vulva was 50 Gy in 25 fractions to the 
vulva and bilateral inguinofemoral lymph nodes with the boost of 16 Gy in 8 












Methodology of sample collection and neopterin assessment has been described in 
Part 1 of the study 
 




FIGURE 23- Number of samples analyzed the part 2 of the study on patients in cohort B.  




6.2.3 Statistics  
Urinary neopterin concentrations before and during radiotherapy were 
compared using Wilcoxon signed rank test  
The decision on statistical significance was based on p = 0.05 level.  
The analyses were performed with NCSS software (Number Cruncher 
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1! ! 10! 256±110! 284.00! S!
2! 2±2! 10! 248±99! 254.00! 0.846!
3! 4±2! 10! 288±85! 303.00! 0.541!
4! 5±2! 10! 230±77! 250.00! 0.232!
5! 6±2! 10! 260±57! 265.00! 1.000!
6! 7±2! 10! 304±135! 277.50! 0.770!
7! 9±3! 10! 279±117! 285.00! 0.415!
8! 10±3! 10! 286±112! 268.50! 0.232!
9! 11±3! 9! 262±119! 246.00! 0.652!
10! 12±3! 9! 267±106! 222.00! 0.250!
11! 14±3! 9! 280±126! 245.00! 0.820!
12! 15±3! 9! 328±215! 235.00! 0.477!
13! 19±8! 9! 273±135! 265.00! 0.570!
14! 20±8! 9! 295±128! 284.00! 0.426!
15! 21±8! 9! 289±218! 199.00! 0.910!
16! 22±8! 9! 301±150! 229.00! 0.441!
17! 24±9! 9! 333±171! 311.00! 0.203!
18! 25±9! 8! 334±296! 235.00! 0.383!
19! 27±9! 8! 236±203! 188.00! 0.195!
20! 29±10! 8! 249±170! 190.50! 0.844!
21! 31±10! 8! 275±177! 195.00! 0.641!
22! 34±11! 8! 263±130! 216.50! 0.461!
23! 32±8! 7! 248±217! 156.00! 0.938!
24! 34±8! 7! 259±152! 189.00! 0.446!
25! 37±9! 6! 293±142! 221.00! 0.219!
&
Table 6. Urinary neopterin in patients of cohort B during the course of pelvic radiation 
Shown are the mean ± standard deviation (SD) of interval between the treatment start and 
sample collection, number of patients examined, mean ± SD of urinary neopterin and p-value 









FIGURE 24 The course of urinary neopterin concentrations in patients 1 and 2 cohort B is 
shown. 
Patient 1 had stage III B cervical carcinoma and baseline neopterin 
concentrations on the upper limits of the normal range (205 µmol/mol creatinine).  
External beam radiotherapy was started on the day of the visit 1 and administration of 
cisplatin was initiated on the day of the visit 4. Uterovaginal brachytherapy was 
started the day before the visit 35. Clinically, the course of treatment of this patient 
was uneventful. The therapy was complicated only by mild (grade 2) leukopenia. 
Only mild fluctuations of urinary neopterin concentrations were observed that were 
not accompanied by clinical symptoms. 
Patient 2 who had stage III B cervical carcinoma and increased baseline 
urinary neopterin concentrations  ( 301 µmol/mol creatinine) started external beam 
radiotherapy on the day of the visit 1 and the first administration of cisplatin on the 
day of the visit 6. Uterovaginal brachytherapy was initiated on the day of the visit 30, 
and continued for 6 fractions, with the last fraction administered on the days of the 
visit 39. On the day of the visit 37 the patient reported a burning sensation in the 
genital area. Systemic administration of ciprofloxacin and metronidazole was started 
and continued for 10 days. This episode coincided with a marked increase in urinary 
neopterin concentrations. Peak urinary neopterin level of 1187 µmol/mol creatinine 



















FIGURE 25. Urinary neopterin concentrations during the course of chemoradiation in 
patients 3 to 6 of cohort B 
 The figure shows the course of urinary neopterin during chemoradiation in 4 
patients with cervical carcinoma. The marked increase of urinary neopterin 
concentrations in patient 5 starting with visit 11 was associated with dyspeptic 
complaints accompanied by diarrhea and fatigue. Subsequently, the patient had skin 
rash. The peaks of urinary neopterin concentrations in patients 3 and 4 were 











































FIGURE 26. Urinary neopterin concentrations during the course of chemoradiation in 
patients 7 to 10 of cohort B 
 The figure shows the course of urinary neopterin during chemoradiation in 4 
patients. In patient 8 the peak urinary concentration an the day of the visit 12 
coincided with the manifestation of skin rash on lower extremities. Other peak 
neopterin values were accompanied only by minor complaints. While, patients 7, 8 
and 9 had cervical carcinoma, patient 10 had recurrent carcinoma of the vulva and 
























































Summary of results in cohort B  
 
Baseline urinary neopterin concentrations were, generally, above the normal 
range. Urinary neopterin concentrations were relatively stable during the first five 
weeks of combined (chemo) radiation.  
Marked peaks of neopterin concentrations reflected the emergence of 
complications.  No statistically significant changes were observed when neopterin 
concentrations at each visit were compared to baseline using the Wilcoxon signed 
rank test.  
In nine patients with cervical cancer treated with chemo radiation, no 
significant difference was observed between urinary neopterin concentrations before 
and at the end of treatment after (mean±Standard deviation) 47 ± 12 days (245 ±  111 
vs 285± 121 µmol/mol creatinine   P  = 0.477)  
 
The Friedman test performed on the data of cervical cancer patients treated 


























 The study of the host immune response and immunomodulation promises to 
unravel new facets of pathogenesis of cancer and may pave way for new strategies for 
management of malignancy. Hence, biomarkers of immune activity will occupy an 
increasingly important role in modern oncology practice. However, in current clinical 
settings the use of biomarkers associated with the host response to neoplastic process 
is limited [Melichar 2013].  
 Neopterin is a well-established biomarker of immune system activation 
[Melichar et al 2006a, Wachter et al 1989] and prognostic significance of increased 
systemic neopterin concentrations has been demonstrated across a spectrum of 
malignant disorders [Reibneggar et al 1991].  This is based on the results of several 
studies in patients with tumors of variety of primary locations, including colorectal 
carcinoma, where increased serum or urinary neopterin concentrations were 
associated with poor prognosis [Melichar et al 2006a, Weiss et al 1993].  Our study 
was designed to test these findings and to establish the reproducibility of these results 
in clinical setting.   
 In addition, an anticancer therapy-induced rise of urinary neopterin 
concentrations has been described after the administration of chemotherapy or 
cytokines [Melichar et al 2006a, Melichar et al 2008a] and radiotherapy-associated 
changes have also been documented. Targeted therapy is a latest addition in the 
arsenal of oncologists. However, so far the information about neopterin in patients 
treated with targeted agents such as cetuximab is limited.  
 Our project was designed to test the clinical application of neopterin in management 
cancer patients.  
Our data was able to demonstrate: 
1. That the pretreatment neopterin correlated with prognosis of patients of 
metastatic colorectal carcinoma. 
2. The differential behavior of urinary neopterin concentrations during anticancer 
therapy with the targeted agent (cetuximab) in combination with 
chemotherapy.   
3. That rise or spikes in urinary neopterin concentration may indicate the 






When treatment was initiated in our cohort of patients with colorectal cancer 
(cohort A) a significant increase in urinary neopterin was observed in patients with 
normal range of pretreatment concentration, while a decreasing trend was evident in 
patients with high initial urinary neopterin.  These changes in neopterin levels 
underline the presence of systemic immune activation during the systemic therapy and 
use of cetuximab.  Only one patient in our group was treated with cetuximab 
monotherapy, and hence it is difficult to discern the effects of irinotecan-based 
chemotherapy and administration of cetuximab. 
The present study corroborates the observation of negative prognostic 
significance of increased urinary neopterin concentrations in patients with metastatic 
colorectal carcinoma [Melichar et al 2006c, Weiss et al 1993] and extends to patients 
treated in second or higher line of therapy with combination of chemotherapy and 
cetuximab.  Whether the negative prognostic significance of high urinary neopterin 
concentrations observed in the present cohort is associated with the absence of 
systemic immune response, and if that is reflected by a lack of an increase of urinary 
neopterin concentrations, is a subject of further investigation.  
Our study has corroborated the prior reports on correlation of neopterin 
concentrations with various laboratory parameters. We were able to identify a 
correlation between urinary neopterin, peripheral blood leukocyte count, 
hemoglobin, and CEA concentration. These correlations could partly explain the 
association between high urinary neopterin concentrations and poor prognosis in the 
patients of cohort A. The inverse correlation of hemoglobin with neopterin 
concentrations that has been studied extensively [Melichar et al 2008a, Fuchs et al 
1991, Sramek et al 2013] has also been demonstrated in our cohort A. Previously, in 
a retrospective analysis of patients of advanced colorectal carcinoma neopterin along 
with CEA was found to be an indicator of prognosis [Melichar et al 2006c]. 
However, it was a retrospective analysis and our current prospective data 
corroborates these findings. In addition to the methodology, the major difference is 
the use of cetuximab in our present patient group. Again, 214 were the cut off 
between the two groups as in our present study. These cutoff limits were selected 
based on medians of respective parameters in the studied group. 
Targeted anticancer therapy has been a promising development and has proved 





cancer patient.  In spite of several studies, the precise the mechanism of action of 
many targeted agents is not entirely clear. In addition to targeting the intercellular 
pathways it may involve, at least in part, the activation of the immune response.  The 
targeted agent that was administered to patients in our study was cetuximab.   
 Cetuximab is an IgG1 class antibody that could trigger antibody-dependent 
cell-mediated cytotoxicity [Messersmith et al 2007] and there is data indicating that, 
indeed, the activation of host response may be one of the mechanisms responsible for 
antitumor activity of cetuximab [Zhang et al 2007, Bibeau et al 2009]. The changes of 
urinary neopterin observed during the treatment in the present study further supports 
the notion that the activation of host response may represent one of the mechanisms 
behind anti-tumor activity of cetuximab alone or in combination with cytotoxic 
chemotherapy.   A rise in the parameters of immune or inflammatory response may 
have different implications and reflect association with effective host response 
associated with tumor eradication.   
On the other hand, increased neopterin concentrations before the start of 
therapy may indicate the presence of a state refractory to further stimulation of the 
immune system.  In earlier studies, correlations were observed between lower 
numbers or impaired function of lymphocytes or dendritic cells and neopterin 
concentrations [Melichar et al 2001]. Thus, increased neopterin concentrations are 
thought to reflect immune dysregulation [Melichar et al 2006a].  
  There have been reports showing that when the daily monitoring of urinary 
neopterin was performed in cancer patients, an increase in neopterin concentrations 
preceded complications while a decrease in urinary neopterin was associated with 
tumor control [Melichar et al 2007].  Reports from studies based on patients with non-
neoplastic disorders have been encouraging. For example daily neopterin 
measurements were reported in organ transplant recipients and a rise in urinary 
neopterin was an early indicator of acute complications [Chin et al 2008].  In 
oncology practice complications can also be due the direct side effects or adverse 
reactions to anticancer treatment. While some side effects of anticancer therapy, e.g., 
skin or eye toxicity [Melichar and Nemcova 2007], may be assessed directly by visual 
inspection, several adverse events of the treatment are not so easy to detect or 
evaluate. Anticancer therapies also make patients vulnerable to other complications 






As mentioned earlier some side effects might not be visible but can yet be 
clinically significant.  Neopterin might be a useful to forewarn or monitor such 
complication. The best example of this potential is the successful implementation of 
neopterin for clinical practice has been in the area of transfusions.  
In their communication to Lancet, Operskalski et al. highlighted the utility of 
neopterin in blood transfusion. They argued that there will be newer undiscovered 
viruses that would need to be screened prior to transfusions and due to its non-
specificity but high sensitivity, neopterin is an excellent marker to screen acute 
infective phases in the donor blood. [Operkalski et al 1997]. This communication 
sums up the reason why Austria has used neopterin as a screening method in blood 
products since 1994. Screening of blood donations with neopterin allowed the 
detection and exclusion of viral infections during the acute phase when virus load is 
highest and allows to further shortening the diagnostic window in addition to specific 
serologic screening methods [Zangerle et al 1992, Reissigl et al 1989]. In this way 
subclinical infections or silent systemic disorders may be detected in a higher 
frequency by increased neopterin concentrations and suspicious blood units are 
discarded to increase the security of transfusion [Hönlinger et al 1989].  
 In case of management of cancer patients the complications related or unrelated 
to therapy could, depending on their grade or extent, have a huge impact on the 
overall outcome of treatment.  A practicing oncologist is always weary of such a 
situation. It is not uncommon for a patient to miss chemotherapy or other treatment 
schedule because of certain complications.  An observation of routine oncology 
practice would reveal that complications might lead to the following.  
Unwanted delays – Example - mucositis related to a drug or radiotherapy affect the 
patients swallowing and hence the oral treatment cannot be continued; it also leads to 
nutritional deficiency leading to morbidity.  
 Dose reduction - Example - Neuropathy can have an adverse impact on the 
performance status, thereby mandating reduction in the dose.  
 Hospital admissions - Example - Myelosuppression can lead to anemia or bleeding 
and require transfusion.  





complication of cytotoxic therapy. Some drugs can cause anaphylactic reactions too. 
All the above can derail the treatment plan either in part or in its entirety.  
Hence, a tool for objective assessment of complication is highly desirable in clinical 
practice. Neopterin has been associated with side effects and complications in 
previous studies and our study corroborates the findings.  With further to data support 
our findings, the measurement of neopterin in the urine could offer a non-invasive 
approach for the assessment of the condition of the patient, and it could be of special 
value in the outpatient setting.  
 In the second part of our study we monitored serial urinary neopterin levels in 
patients of gynecological malignancy who were undergoing pelvic radiotherapy with 
concomitant chemotherapy (cohort B).   Pelvic chemoradiation is an effective 
therapeutic modality in adjuvant treatment as well as in patients with inoperable 
cervical carcinoma [Morris et al 1999, Keys et al 1999].  However, chemoradiation is 
an aggressive therapy that results in a significant percentage of serious, in extreme 
cases even lethal, complications. Timely management of complications of therapy is 
of great importance.  
 In our study, we were unable to detect any significant increase in urinary 
neopterin concentrations during external beam radiation in patients with 
gynecological cancer. As explained in the previous section, all but one of our patients 
had cervical carcinoma. Our data indicated that, in the absence of complications, 
urinary neopterin concentrations show only mild fluctuation throughout the course of 
therapy without a significant trend.  
 These negative findings contrast with our data from the cohort A where we 
found definitive change in urinary neopterin levels in response to the anticancer 
therapy and also with the recently reported in a cohort of patients with head and neck 
carcinoma [Holeckova et al 2012, Holecková et al 2013]. In fact, it might be expected 
that the chemoradiation regimen used in cervical cancer would result in a marked 
activation of systemic immune response reflected in increased neopterin 
concentrations.  However, our results did not qualify the above statement which is 
based on the fact that all major cell populations responsible for the host response to 
neoplasia are present in the peritoneal cavity, including monocytes/macrophages 





manipulations [Freedman et al 2003]. Moreover, both chemotherapy and radiation 
cause a significant damage to the intestinal barrier [Dvorak et al 2010] that may result 
in the activation of the systemic immune response. This could not be observed in 
cohort B.  However, in individual patients of cohort B, a marked increase (spikes) in 
urinary neopterin concentration was noted. These spikes in neopterin levels coincided 
with clinically demonstrable complications.  The fact that the neopterin failed to 
change in response to treatment provided a backdrop plateau to observe the spikes in 
urinary neopterin levels. Hence, we can say that in cohort B the rise in neopterin 
reflected the emergence of the complications during therapy rather than a direct effect 
of the treatment itself.  True to the non-specific character of neopterin, the rise did not 
accompany any specific condition but were associated with different complications. 
Similar to the results of the present study, no significant increase in urinary neopterin 
concentrations was reported earlier in patients with rectal cancer treated with 
chemoradiation [Dvorak et al 2010]. Why these groups behaved differently is a matter 
of further investigation. 
           In our study, the pretreatment urinary neopterin concentrations were relatively 
high and above normal range in most patients.  High neopterin concentrations in 
cancer patients may be associated with a down-regulation of immune response [ 
Melichar et al 1996, Melichar et al 2001] and the immune system plays an important 
role in the progression of abdominal and pelvic neoplasms [Melichar et al 2002]. 
High neopterin concentrations may decrease as a consequence of tumor control. 
Increased urinary neopterin concentration is also an independent parameter associated 
with poor prognosis in cervical cancer [Reibnegger et al 1996]. However, in the 
present study, the number of patients examined was too small to analyze an 
association between neopterin concentrations before or during chemoradiation with 
the outcome. 
 The fact that neopterin concentrations may also increase as a result of non-
neoplastic disorders represents an advantage and assessment of neopterin levels may 
help to detect or monitor a wide range of different complications that could impact the 
effectiveness anticancer therapy. Neopterin levels do reflect immune activation in 
cancer patients however it lacks the specificity required to formulate a strategy in a 
cancer subtypes.  However, several problems associated with different malignancy 
and with different anticancer treatment are common and even their manifestations are 





chemotherapy and of targeted therapy too.   
 There are several possible explanations for the negative findings in the present 
study with cohort B.  Our cohort, comprising of 10 patients, might be relatively small 
group to predict general trend.  The samples in our study were usually not collected 
during treatment interruptions, making comparison of values obtained at the same 
visit in different patients difficult. Consequently, statistical analyses performed here 
have to be regarded as exploratory at best. Future investigations on a larger cohort of 
patients to investigate the potential of neopterin as a biomarker for early detection of 
complications during pelvic radiotherapy as well as other anticancer treatment ought 
to be undertaken.  
 The association of the changes in urinary neopterin concentrations during the 
treatment with biological therapy to survival could be investigated in other cancer 
type and with other agents. It might also give further insights to the mechanism of 
action of targeted therapy and its interaction with systemic immune activity.  
In light of our results we believe that neopterin is a promising biomarker that serves 
not only as a tool for laboratory based investigations and research but that it also has a 
potential to be of assistance in the clinical management of several aspects in oncology 
practice. This includes prognosticating, monitoring complications and response to 





















 Host immune activity plays a vital role in the pathogenesis, prognosis and 
response to treatment in cancer patients.  Neopterin, a laboratory biomarker of 
immune activation, was tested for its potential use in clinical setting during the 
management of cancer patients.   
 Our study was focused on three main aspects namely prognosis, monitoring 
response to therapy and monitoring complications.  
 We found that in cohort A, a higher neopterin levels were associated with poor 
prognosis.  Neopterin levels in patients with higher initial levels, fell while on 
treatment.  In this cohort neopterin levels showed correlation to hemoglobin levels, 
white cell count and CEA. Based on the results of the first part we could possibly 
conclude that urinary neopterin could be prognostic biomarker in patients treated with 
systemic therapy in second or higher line of treatment for metastatic colorectal cancer.    
 Interestingly, traditional anticancer therapy and even the newer targeted therapy 
are proving to have immunomodulatory effects contributing to their anticancer 
activity. We were able to monitor the fluctuations and trends of change in neopterin 
levels in cohort A, whilst on treatment.  A marked increase of urinary neopterin 
observed during the treatment may indicate an activation of immune response.  
In cohort B, pretreatment neopterin levels were generally higher.  Contrary to 
our expectation, in this part of the study we were unable to detect any significant 
change in urinary neopterin concentration in patients treated with pelvic (chemo) 
radiation.  However, we were able to demonstrate that urinary neopterin 
concentrations may reflect the complications during therapy and could be used to 
monitor the condition of the patient during the treatment.   
The advantage being that a spiking neopterin level could alert a vigilant 
physician who can anticipate complications or ensure that adverse events are picked 
up in time.  
In our study we were able to recruit patient of different kinds of malignancies. 
We monitored neopterin in patients while undergoing all established non-surgical 





looked as various aspects like, prognosis, monitoring response to therapy and 
monitoring complication in cancer patients.  
 The ability of measuring neopterin in urine gives it a unique edge over other 
biomarker for example, CRP, ferritin and albumin, all of which require phlebotomy.   
 Taking into consideration patient discomfort, problems like thrombophlebitis 
due to repeated venipuncture, the requirement of trained phlebotomy personal, the 
risk of contamination and sharps injury, one could argue that measurement of a 
urinary biomarker is more patient friendly and cost effective.  
It must be mentioned that this is probably a unique study in terms of 
monitoring neopterin levels during cetuximab infusion in this patient subset.  
Furthermore, the findings from this study have also added to the current body of work 
on neopterin in form of publications and it not only corroborates previous findings but 
also contributes to the knowledge. With the evidence of therapy related changes in 
neopterin levels the current findings also adds to a growing body of literature 
establishing immune mechanisms of targeted agents.  
The intention of our project was to test the hypothesis that neopterin has the 
potential to be of use in routine oncology practice. We believe that we have been able 
to confirm that neopterin has a potential role in prognosticating and monitoring 
response to therapy and complications in patients undergoing anticancer therapy.    
In view of our result it would be fair to say that neopterin has the potential to walk out 
of the realms of laboratory research into the domain of routine clinical activity in 
modern oncology practice.  It must be added that much work with stronger evidence 
will be needed to sieve out clinical applications of neopterin in the clinics. Our study 
on the specific issues of assessment of prognosis, monitoring response to therapy and 











9. Limitations of the current study 
Although the study has successfully demonstrated that neopterin can 
potentially play a role in clinical settings, our study did have certain limitations. 
The generalizability of these results is subject to certain limitations. For 
instance, there is a difference in the percentages of patients with different malignant 
pathologies in terms of rise of neopterin.    In our study we had recruited patient with 
two different common types of cancer, however in order to recommend the use of 
neopterin in routine oncology practice similar prospective studies in other patient 
groups ought to undertaken.   
In addition, our study was limited with the number of patients and sample size. 
It was possibly because of this drawback that we were unable to demonstrate therapy 
related change or a trend in cohort B.  Hence the results in second cohort may be 
regarded as exploratory at best.  Our study was based in a single center and the 
number of patients qualifying for study can be limited. Hence, a larger multi-centric 
study with neopterin to address specific question could be designed.  
Secondly, we were not able to collect sample from patients during bank 
holidays and weekend in the second part of our study. We could have missed small 
fluctuations in neopterin levels during this period. Further research may shed light on 
why certain patients undergoing chemoradiotherapy do not show changes in neopterin 
levels.  
Further refinements and larger studies to investigate specific use of neopterin 











 Our understanding of immune system, its role in cancer development and the 
immune escape mechanism of malignant cells is evolving. Neopterin with its 
characteristic property of reflecting the immune activation provides an essential tool 
in further research.  The role of neopterin and how it affects the microscopic and 
macroscopic homeostatic mechanism also needs to be looked at.  In addition, with 
further expansion of clinical studies and collecting evidence of the correlation of 
neopterin with various laboratory and clinical parameters we might be able to soon 
see this long lost compound on the panel of investigations that oncologist request 
while managing specific patients.  
 Our research has also thrown up questions that need to be answered by further 
investigations.  It will be interesting to see if a larger study on patients with pelvic 
chemoradiation would yield a different result.   A multi-centric study with specific 
subdivision based on tumor types and stages and treatment modality could be 
undertaken to expound on the current results.  
  It will also be very interesting to observe the effect of new immunomodulatory 
anticancer therapy on neopterin levels.  The urinary neopterin levels in responders and 
non-responders to these drugs could be a good initial starting point.  
Our study was also able to demonstrate that neopterin could be a potential tool 
in better understating of the effects of targeted therapy on the immune system. This 
could be potentially used for other studies to understand the mechanism of action of 
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FIGURE 1.  Neopterin:  2-amino -4-oxo-6 –(derythro-1', 2', 3'-trihydroxypropyl)-
pteridine  
 
FIGURE 2. In various cells the Th1-type cytokine IFN-gamma (IFN-γ) induces the 
GTP-cyclohydrolase I (GCH I) to produce 7, 8-dihydroneopterintriphosphate. Due to 
a deficiency in 6 -pyruvoyltetrahydropterin synthase (PTPS) in human monocyte-
derived macrophages and dendritic cells, the production of 5, 6, 7, 8-
tetrahydrobiopterin is almost zero and neopterin is produced in high concentrations. 
Ref Becker et al. 
 
FIGURE 3: IFN-Gamma induce production of ROS, Neopterin and TNF alpha  
 
FIGURE 4: Induction of neopterin formation in brain cells. Proinflammatory 
cytokines like interferon-γ (IFN-γ) induce expression of GTP-cyclohydrolase I in 
various brain cells. As an intermediate product 7, 8-dihydroneopterin-triphosphate is 
produced which is further converted by pyruvoyl-tetrahydropterin synthase (PTPS) to 
form 5, 6, 7, 8-tetrahydrobiopterin (BH4), the cofactor of several aromatic amino acid 
monooxygenases that are involved in the production of tyrosine, L-DOPA, serotonin 
and nitric oxide. Different from neurons, monocytic cells possess only low 
constitutive activity of PTPS. Thus, 7, 8-dihydroneopterin-triphosphate does not 
undergo conversion to BH4, rather it is dephosphorylated and oxidized to neopterin in 
non-enzymatic reactions. 
 
FIGURE 5. HPLCC apparatus and setup   
 







FIGURE 7. Number of samples collected in Part 1 of the study with patients in Group A. 
Figure 7 shows the sample number collected serially during the treatment in study group A 
 
FIGURE 8. Patients of cohort A in whom serial urinary samples were collected were divided in 
two groups based on High and Low Neopterin/Creatinine ratio (214 as the cut off) are shown in 
Figure 8 
 
FIGURE 9. The changes in urinary neopterin concentrations during the course of 
therapy in patients 1-6 of cohort A are shown in Figure 9. 
 
FIGURE 10.  The changes in urinary neopterin concentrations during the course of 
therapy in patients 7-12 of cohort A are shown in Figure 10. 
 
FIGURE 11. The changes in urinary neopterin concentrations during the course of 
therapy in patients13-18 of cohort A are shown in Figure 11. 
FIGURE 12.  The changes in urinary neopterin concentrations during the course of 
therapy in patients 19-24 of cohort A are shown in Figure 12. 
 
FIGURE 13. The changes in urinary neopterin concentrations during the course of 
therapy in patients 25-30 of cohort A are shown in Figure 13. 
 
FIGURE 14. The changes in urinary neopterin concentrations during the course of 
therapy in patients 31-36 of cohort A are shown in Figure 14. 
 
FIGURE 15. The course of urinary neopterin concentrations during the course of 
therapy in a 78-year-old patient (patient no 9 of cohort A) treated with single-agent 
cetuximab is shown above/ in Figure 15. 
 
FIGURE 16. Stacked line graph showing trends in patients with Neopterin/ 
Creatinine < 214 in Group A.  The stacked lines showing trend of changes in urinary 
neopterin levels in patients with pretreatment neopterin <214 are shown in Figure 16. 






FIGURE 17. Stacked line graph showing trends in patients with Neopterin/ 
Creatinine > 214 in Group A. The stacked lines showing trend of changes in urinary 
neopterin levels in patients with pretreatment neopterin >214 are shown in Figure 17. 
A general fall in neopterin levels was noted on commencement of anticancer therapy. 
 
FIGURE 18. Correlation between urinary neopterin and hemoglobin in patients of 
group A 
 
FIGURE 19. Correlation between peripheral blood leukocyte count and urinary 
neopterin concentrations in patients of group A 
 
 
FIGURE 20. Correlation between carcinoembryonic antigen and urinary neopterin 
concentrations in cohort A  
 
FIGURE 21. Survival curves cohort A - At the time of the analysis, 44 patients died while 
one patient was alive after 74 months. Survival of patients with urinary neopterin 
concentration of 214 [µmol/mol creatinine ] or above was significantly inferior compared 
to patients with initial urinary neopterin below 214 [µmol/mol creatinine ] (median 10.1 
vs. 17.7 months, p<0.05; Figure 21). 
 
FIGURE 22 – Patients characteristics in cohort B. The division of patients in chort B 
based on diagnosis is demonstrated in Figure 22 
FIGURE 23- Number of samples analyzed the part 2 of the study on patients in 
cohort B.  Number of daily samples analyzed the part 2 of the study on patients in 







FIGURE 24 The course of urinary neopterin concentrations in patients 1 and 2 cohort 
B is shown. 
FIGURE 25. Urinary neopterin concentrations during the course of chemoradiation 
in patients 3 to 6 of cohort B 
 
FIGURE 26. Urinary neopterin concentrations during the course of chemoradiation 





















Table 1: Neopterin concentrations (mean + S.D. and 97.5th percentiles) in urine of 
healthy individuals  
 
Table 2: depictions of evidence in literature on tumor types and the use of neopterin 
in prognosis  (Table modified from Murr et al, 2002. based on new evidence) 
Table 3 .The mean ± standard deviation of neopterin levels in the two groups  a p < 
0.05, b p < 0.01, c p < 0.001, d p < 0.0001. The standard deviations of neopterin in high 
and low neopterin level groups are shown in table 3 
 
Table 4a: Serial Urinary neopterin levels during the systemic therapy in group A  
 
Table  4b : Pretreatment neopterin in patients of cohort A in whom serial sample 
collections could not completed  
 
Table 5. The cohort of patients studied in cohort B. Age group, histology and staging  
 
Table 6. Urinary neopterin in patients of cohort B during the course of pelvic 
radiation . Shown are the mean ± standard deviation (SD) of interval between the 
treatment start and sample collection, number of patients examined, mean ± SD of 
urinary neopterin and p-value (Wilcoxon signed rank test) at the respective visit. 
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